What the Data Show," Dr. Vaduganathan walks through the cardiovascular outcomes trials that built the evidence base for SGLT2 i ...
Ōtākou Whakaihu Waka researchers have been part of two studies in the battle against drug resistant strains of Mycobacterium tuberculosis, the cause of tuberculosis. Co-author on both studies, Dr.
A new Peter Mac study using a pioneering drug has successfully controlled the growth of tumors and overcome existing drug resistance in multiple cancer types. An enzyme critically associated with ...
SK Biopharmaceuticals Co. Ltd. signed a licensing and equity deal agreement to acquire global rights to 1ST-104, a preclinical type II LRRK2/c-Abl tyrosine kinase inhibitor, for Parkinson’s disease ...
TAMPA, Fla., March 31, 2026 (GLOBE NEWSWIRE) -- Inhibitor Therapeutics, Inc. (OTCQB: INTI) ("Inhibitor" or the "Company"), today provided an update on its ongoing pharmacokinetic (PK) clinical program ...
A research team has made a breakthrough in epigenetic drug discovery. The researchers have successfully developed a first-in-class chemical inhibitor that precisely and selectively targets the ATAC ...
CDK 4/6 inhibitors (CDK4/6i) remain part of the standard first-line treatment for patients with hormone receptor–positive metastatic breast cancer, offering demonstrable improvements in both ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results